FormsNet3 - Blank Form


 

 
Sequence Number:    

 

 
Date Received: __ __ __ __ - __ __- __ __  

 

 
CIBMTR Center Number:    

 

 
CIBMTR Recipient ID:    

 

 
Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __  

HCT Type: (check all that apply) 

 

 
Autologous

 

 
Allogeneic, unrelated

 

 
Allogeneic, related

Product type: (check all that apply) 

 

 
Bone marrow

 

 
PBSC

 

 
Single cord blood unit

 

 
Multiple cord blood units

 

 
Other product

 

 
Specify:    

 

 
Visit

  
 

100 day  
 

6 months  
 

1 year  
 

2 years  
 

> 2 years,  

 

 
Specify:    

 

 
1  Compared to the disease status prior to the preparative regimen, what was the best response to HCT since the date of the last report?

    (Include response to any therapy given for post-HCT maintenance or consolidation, but exclude any therapy given for relapsed, persistent, or progressive disease.)  

 
Continued complete remission (CCR)  -for patients transplant in CR 

 
Complete 

remission (CR)  

-requires all of the following, maintained for ≥ 4 weeks: *bone marrow evaluation: <5% myeloblasts with normal maturation of all cell lines *peripheral 
blood evaluation: hemoglobin ≥ 11g/dL untransfused and without erythropoietin support; ANC ≥ 1000/mm3 without myeloid growth factor support; 
platelets ≥ 100 x 109/L without thrombopoietic support; 0% blasts  

 
Hematologic 

improvement 

(HI)  

-requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to 
determine HI response: * HI-E hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC units 
transfused in 8 weeks by ≥ 4 units compared to the pre-treatment transfusion number in 8 weeks *HI-P for pre-treatment platelet count of > 20 x 109 L, 
platelet absolute increase of ≥ 30 x 109 L; for pre-treatment platelet count of < 20 x 109 L, platelet absolute increase of ≥ 20 x 109 L and ≥ 100% from pre-
treatment level *HI-N neutrophil count increase of ≥ 100% from pre-treatment level and an absolute increase of ≥ 500/mm3   

 
No response (NR) / stable disease (SD)  -does not meet the criteria for at least HI, but no evidence of disease progression 

 
Progression from hematologic 

improvement (Prog from HI)  

-requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): * ≥ 
50% reduction from maximum response levels in granulocytes or platelets *reduction in hemoglobin by ≥1.5 g/dL *transfusion 
dependence  

 
Relapse from complete 

remission (rel from CR)  

-requires at least one of the following: *return to pre-treatment bone marrow blast percentage *decrease of ≥ 50% from maximum 
response levels in granulocytes or platelets *transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy  

 
Progression to AML  -≥20% blasts in the blood or bone marrow 

 

 
2  Was the date of best response previously reported?

    
 

yes  
 

no  

 

 
3  Date assessed: __ __ __ __ - __ __- __ __  

  Key Fields 

Disease Assessment at the Time of Best Response to HCT Questions: 1 - 20

Form 2114 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data  
Center:  CRID: 

             CIBMTR Form 2114 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 1 / 4



 

 
4  Was the disease status assessed by molecular testing (e.g. PCR)?

    
 

yes  
 

no  

 

 
5  Date assessed: __ __ __ __ - __ __- __ __  

 

 
6  Was disease detected?

    
 

yes  
 

no  

 

 
7  Was the status considered a disease relapse or progression?

    
 

yes  
 

no  

 

 
8  Was the disease status assessed via flow cytometry?

    
 

yes  
 

no  

 

 
9  Date assessed: __ __ __ __ - __ __- __ __  

 

 
10  Was disease detected?

    
 

yes  
 

no  

 

 
11  Was the status considered a disease relapse or progression?

    
 

yes  
 

no  

 

 
12  Was the disease status assessed by cytogenetic testing (conventional or FISH)?

    
 

yes  
 

no  

 

 
13  Was the disease status assessed via FISH?

    
 

yes  
 

no  

 

 
14  Date assessed: __ __ __ __ - __ __- __ __  

 

 
15  Was disease detected?

    
 

yes  
 

no  

 

 
16  Was the status considered a disease relapse or progression?

    
 

yes  
 

no  

 

 
17  Was the disease status assessed via conventional cytogenetics?

    
 

yes  
 

no  

 

 
18  Date assessed: __ __ __ __ - __ __- __ __  

 

 
19  Was disease detected?

    
 

yes  
 

no  

 

 
20  Was the status considered a disease relapse or progression?

    
 

yes  
 

no  

 

 
21  Was a disease relapse or progression detected by molecular testing (e.g. PCR)?

    
 

yes  
 

no  

 

 
22  Date assessed: __ __ __ __ - __ __- __ __  

 

 
23  Was a disease relapse or progression detected via flow cytometry?

    
 

yes  
 

no  

  Disease Relapse or Progression Post-HCT Questions: 21 - 31

Form 2114 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data  
Center:  CRID: 

             CIBMTR Form 2114 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 2 / 4



 

 
24  Date assessed: __ __ __ __ - __ __- __ __  

 

 
25  Was a disease relapse or progression detected by cytogenetic testing (conventional or FISH)?

    
 

yes  
 

no  

 

 
26  Was a disease relapse or progression detected via FISH?

    
 

yes  
 

no  

 

 
27  Date assessed: __ __ __ __ - __ __- __ __  

 

 
28  Was a disease relapse or progression detected via conventional cytogenetics?

    
 

yes  
 

no  

 

 
29  Date assessed: __ __ __ __ - __ __- __ __  

 

 
30  Was a disease relapse or progression detected by clinical / hematologic assessment?

    
 

yes  
 

no  

 

 
31  Date assessed: __ __ __ __ - __ __- __ __  

 

 
32  Was the bone marrow examined (post-HCT) since the date of the last report?

    
 

yes  
 

no  
 

Unknown  

 

 
33  Date sample collected: __ __ __ __ - __ __- __ __  

 

 
34  Blasts in bone marrow

    
 

Known  
 

Unknown  

 

 
35     % 

 

 
36  Did the recipient have myelofibrosis since the date of the last report?

    
 

yes  
 

no  
 

Unknown  

 

 
37  Specify the status of marrow fibrosis since the date of the last report   

 

 
38  What is the current disease status?

    
 

Complete 

remission (CR)  

— requires all of the following, maintained for ≥ 4 weeks: * bone marrow evaluation: <  5% myeloblasts with normal maturation of all cell lines * 
peripheral blood evaluation: hemoglobin ≥ 11 g/dL untransfused and without erythropoietin support; ANC ≥ 1000 / mm3  without myeloid growth factor 
support; platelets ≥ 100 x 109 /L without thrombopoietic support; 0% blasts   

 
Hematologic 

improvement 

(HI)  

— requires one measurement of the following, maintained for ≥ 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to 
determine HI response: * HI-E – hemoglobin increase of ≥ 1.5 g/dL untransfused; for RBC transfusions performed for Hgb ≤ 9.0, reduction in RBC 
units transfused in 8 weeks by ≥ 4 units compared to the pre-treatment transfusion number in 8 weeks * HI-P – for pre-treatment platelet count of > 20 x 
109/L, platelet absolute increase of ≥ 30 x 109/L; for pre-treatment platelet count of < 20 x 109/L, platelet absolute increase of ≥ 20 x 109/L and ≥ 100% 
from pre-treatment level  * HI-N – neutrophil count increase of ≥ 100% from pre-treatment level and an absolute increase of ≥ 500 / mm3   

 
No response (NR) / stable disease (SD)  — does not meet the criteria for at least HI, but no evidence of disease progression 

 
Progression from hematologic 

improvement (Prog from HI)  

— requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): 
* ≥ 50% reduction from maximum response levels in granulocytes or platelets * reduction in hemoglobin by ≥ 1.5 g/dL *transfusion 
dependence  

 
Relapse from complete 

remission (Rel from CR)  

— requires at least one of the following: * return to pre-treatment bone marrow blast percentage * decrease of ≥ 50% from maximum 
response levels in granulocytes or platelets * transfusion dependence, or hemoglobin level ≥ 1.5 g/dL lower than prior to therapy  

 
Progression to AML — ≥ 20% blasts in the blood or bone marrow 

 
Not assessed  

 

 
39  Was the recipient in molecular remission?

    
 

Yes  
 

No  
 

Unknown  
 

Not applicable  

  Laboratory Studies at the Time of Evaluation for this Reporting Period Questions: 32 - 37

  Disease Status at the Time of Evaluation for this Reporting Period Questions: 38 - 41

Form 2114 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data  
Center:  CRID: 

             CIBMTR Form 2114 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 3 / 4



 

 
40  Was the recipient in cytogenetic remission?

    
 

Yes  
 

No  
 

Unknown  
 

Not applicable  

 

 
41  Date assessed: __ __ __ __ - __ __- __ __  

 

 
First Name:    

 

 
Last Name:    

 

 
E-mail address:    

 

 
Date: __ __ __ __ - __ __- __ __  

Form 2114 R3.0: Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data  
Center:  CRID: 

             CIBMTR Form 2114 revision 3.0 last updated October 2013 
Copyright(c) 2012 National Marrow Donor Program and 

The Medical College of Wisconsin, Inc. All rights reserved. 

Page 4 / 4